Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic drug industry Waxman/Hatch agenda to shape debate urged by Rep. Waxman.

This article was originally published in The Tan Sheet

Executive Summary

GENERIC INDUSTRY SHOULD DEVELOP WAXMAN/HATCH AGENDA to address concerns regarding the drug patent law, Rep. Henry Waxman (D-Calif.) suggested at the National Association of Pharmaceutical Manufacturers mid-year meeting in Washington, D.C. June 23. "Oftentimes, the legislative process is responding to those who are coming in with demands," Waxman pointed out. "If you think that you need to press for more changes, you ought to do it," he advised. "The demands that are made may not get granted, but it certainly puts them on the agenda, so I leave it to you to figure out what you want on the agenda."

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts